AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15063379 — intervention group
Group type: COMPARATOR
Intervention: Audio slide presentation
Number of subjects: 0
Study 11961371 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 729
Study 9818860 — intervention group
Group type: EXPERIMENTAL
Intervention: Open craniotomy within 12 hours of ICH symptom onset
Number of subjects: 34
Study 9818860 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 34
Study 8748041 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4-8 mg/day)
Number of subjects: 6
Study 8748041 — intervention group
Group type: COMPARATOR
Intervention: Active controls (haloperidol, perphenazine, zuclopenthixol)
Number of subjects: 6
Study 2497135 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a treatment starting 4-7 days after ovulation (Group 1)
Number of subjects: 44
Study 2497135 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a treatment starting 8-10 days after ovulation (Group 2)
Number of subjects: 44
Study 2497135 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a treatment starting 1-3 days after the onset of menses (Group 3)
Number of subjects: 44
Study 2497135 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 44
Study 142005 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 8-MOP-UVA treatment (12 patients)
Number of subjects: 19
Study 142005 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment (7 patients)
Number of subjects: 19
Study 6983966 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen 150 mg daily, b.i.d. administration
Number of subjects: 80
Study 6983966 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen 300 mg daily, b.i.d. administration
Number of subjects: 80
Study 6983966 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen 300 mg daily, t.i.d. administration
Number of subjects: 80
Study 6983966 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen 300 mg daily
Number of subjects: 80
Study 31438346 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile biofeedback from the posture trainer device
Number of subjects: 0
Study 31438346 — intervention group
Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 0
Study 29242893 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental Tier 2 vocabulary intervention
Number of subjects: 0
Study 29242893 — intervention group
Group type: EXPERIMENTAL
Intervention: First unit benchmark of the intervention
Number of subjects: 0
Study 26771265 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal anesthesia (BIS 40-45)
Number of subjects: 40
Study 26771265 — intervention group
Group type: COMPARATOR
Intervention: High-normal anesthesia (BIS 55-60)
Number of subjects: 40
Study 26771265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 25073833 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pharmacotherapy
Number of subjects: 1065
Study 25073833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1065
Study 25073833 — intervention group
Group type: EXPERIMENTAL
Intervention: High genetic risk with partner smoking
Number of subjects: 1065
Study 25073833 — intervention group
Group type: EXPERIMENTAL
Intervention: High genetic risk without partner smoking
Number of subjects: 1065
Study 21726301 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual edge detection
Number of subjects: 984
Study 21726301 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-automated edge detection
Number of subjects: 984
Study 21726301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (manual reading)
Number of subjects: 984
Study 21726301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (semi-automated reading)
Number of subjects: 984
Study 21726301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (manual reading)
Number of subjects: 984
Study 21726301 — intervention group
Group type: COMPARATOR
Intervention: Placebo (semi-automated reading)
Number of subjects: 984
Study 19841043 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Number of subjects: 1604
Study 19841043 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer sunshine
Number of subjects: 1604
Study 19841043 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D supplements
Number of subjects: 1604
Study 18065577 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO diet (carbohydrate diet)
Number of subjects: 85
Study 18065577 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA diet (monounsaturated fatty acids diet)
Number of subjects: 85
Study 18065577 — intervention group
Group type: COMPARATOR
Intervention: AAD (average American diet)
Number of subjects: 85
Study 14740153 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐hormones (alphacalcidol and calcitriol)
Number of subjects: 17
Study 14740153 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 17
Study 10936784 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase (ALP) activity in patients with CHM
Number of subjects: 12
Study 10936784 — intervention group
Group type: EXPERIMENTAL
Intervention: Localization of enzyme activities in cryosections
Number of subjects: 12
Study 10936784 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermostability of ALP
Number of subjects: 12
Study 10936784 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical inhibition study of ALP
Number of subjects: 12
Study 9410139 — intervention group
Group type: EXPERIMENTAL
Intervention: Folstein's Mini Mental Test (MMT)
Number of subjects: 329
Study 9410139 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobo's Cognitive Mini Exam (CME)
Number of subjects: 329
Study 9410139 — intervention group
Group type: EXPERIMENTAL
Intervention: Isaacs Set test
Number of subjects: 329
Study 8104448 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium and Vecuronium (10:1, 4:1, 1.6:1 dose ratios)
Number of subjects: 30
Study 3594460 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g oxiracetam
Number of subjects: 12
Study 3594460 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 12
Study 28262474 — intervention group
Group type: EXPERIMENTAL
Intervention: eContour (interactive web-based contouring atlas)
Number of subjects: 24
Study 28262474 — intervention group
Group type: COMPARATOR
Intervention: Existing contouring resources
Number of subjects: 24
Study 24730669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 48
Study 24730669 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 48
Study 24730669 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 48
Study 23819964 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist medical and mental health unit
Number of subjects: 600
Study 23819964 — intervention group
Group type: COMPARATOR
Intervention: Standard care (acute geriatric or general medical wards)
Number of subjects: 600
Study 22816729 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg twice daily
Number of subjects: 491
Study 22816729 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 491
Study 22816729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 491
Study 19710003 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-dose end-expiratory CT
Number of subjects: 20
Study 17460786 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER) 3-15 mg/day
Number of subjects: 0
Study 17460786 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Number of subjects: 0
Study 15639696 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA 104 mg/0.65 mL SC injection
Number of subjects: 24
Study 11802821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention programme (15 months)
Number of subjects: 30
Study 11802821 — intervention group
Group type: COMPARATOR
Intervention: Usual classroom programme
Number of subjects: 30
Study 9593010 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine (100 mg orally, twice a day)
Number of subjects: 105
Study 9593010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 9593010 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine
Number of subjects: 105
Study 7507135 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream 0.025%, 0.5% or 1.0% applied three times daily for 4 weeks
Number of subjects: 5
Study 7507135 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 5
Study 3219318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispaghula (14-15 g/d)
Number of subjects: 7
Study 3219318 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum
Number of subjects: 7
Study 3219318 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanthan gum
Number of subjects: 7
Study 3219318 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous polysaccharides (general)
Number of subjects: 7
Study 3219318 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum feeding
Number of subjects: 7
Study 3219318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen production from in vitro cultures
Number of subjects: 7
Study 30963544 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Early Intervention Service (EEIS)
Number of subjects: 217
Study 30963544 — intervention group
Group type: COMPARATOR
Intervention: Regular Care (RC)
Number of subjects: 217
Study 27182992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Number of subjects: 40
Study 27182992 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 40
Study 27182992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 26389600 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n = 59)
Number of subjects: 243
Study 26389600 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (n = 63)
Number of subjects: 243
Study 26389600 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (n = 60)
Number of subjects: 243
Study 26389600 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (n = 61)
Number of subjects: 243
Study 23216584 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipine combination (20 mg/5 mg)
Number of subjects: 276
Study 23216584 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan (20 mg)
Number of subjects: 276
Study 23216584 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg)
Number of subjects: 276
Study 21392672 — intervention group
Group type: EXPERIMENTAL
Intervention: Light buccally directed orthodontic force of 25 g
Number of subjects: 36
Study 21392672 — intervention group
Group type: COMPARATOR
Intervention: Heavy orthodontic force of 225 g
Number of subjects: 36
Study 21392672 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of force application (4, 8, or 12 weeks)
Number of subjects: 36
Study 19216814 — intervention group
Group type: EXPERIMENTAL
Intervention: WHEY+CAS (casein and whey proteins mixture, 22 g protein, 836 kJ)
Number of subjects: 27
Study 19216814 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS (casein only, 22 g protein, 836 kJ)
Number of subjects: 27
Study 17943480 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP+CT (Exposure with Response Prevention + Cognitive Therapy)
Number of subjects: 0
Study 17943480 — intervention group
Group type: COMPARATOR
Intervention: ERP+REL (Exposure with Response Prevention + Relaxation Training)
Number of subjects: 0
Study 17943480 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP+REL
Number of subjects: 0
Study 17943480 — intervention group
Group type: EXPERIMENTAL
Intervention: ERP+CT
Number of subjects: 0
Study 15507959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 61
Study 15507959 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 61
Study 11902300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron at 0.15 mg/kg
Number of subjects: 26
Study 11902300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron at 0.45 mg/kg
Number of subjects: 26
Study 11902300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 26
Study 11579700 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting with a drawsheet
Number of subjects: 42
Study 11579700 — intervention group
Group type: COMPARATOR
Intervention: Lifting without a drawsheet
Number of subjects: 42
Study 8082533 — intervention group
Group type: COMPARATOR
Intervention: Liquid supplement only (Group A)
Number of subjects: 40
Study 8082533 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplement plus an evening meal (Group B)
Number of subjects: 40
Study 2563239 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug
Number of subjects: 12
Study 2563239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31574964 — intervention group
Group type: EXPERIMENTAL
Intervention: Local body vibration (LBV)
Number of subjects: 24
Study 31574964 — intervention group
Group type: COMPARATOR
Intervention: Non-LBV
Number of subjects: 24
Study 28528899 — intervention group
Group type: EXPERIMENTAL
Intervention: American Congress of Obstetricians and Gynecologists summary
Number of subjects: 452
Study 28528899 — intervention group
Group type: EXPERIMENTAL
Intervention: American College of Physicians summary
Number of subjects: 452
Study 28528899 — intervention group
Group type: COMPARATOR
Intervention: First-phase participants (referent group)
Number of subjects: 452
Study 28528899 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall belief about discussing benefits and harms
Number of subjects: 452
Study 24595862 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma choline in nonsmokers (highest vs. lowest quartiles)
Number of subjects: 2568
Study 24595862 — intervention group
Group type: COMPARATOR
Intervention: Plasma choline in smokers
Number of subjects: 2568
Study 24595862 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma choline
Number of subjects: 2568
Study 24595862 — intervention group
Group type: COMPARATOR
Intervention: Plasma betaine
Number of subjects: 2568
Study 24173265 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE membrane removal at 2 weeks (TGr)
Number of subjects: 12
Study 24173265 — intervention group
Group type: COMPARATOR
Intervention: ePTFE membrane removal at 4 weeks (CGr)
Number of subjects: 12
Study 24173265 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TGr and CGr)
Number of subjects: 12
Study 21871931 — intervention group
Group type: EXPERIMENTAL
Intervention: High heart rate reactivity
Number of subjects: 1647
Study 20496613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients supplementation during pregnancy
Number of subjects: 31290
Study 20496613 — intervention group
Group type: COMPARATOR
Intervention: Iron-folic acid supplementation during pregnancy
Number of subjects: 31290
Study 20496613 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of skilled birth attendant (SBA)
Number of subjects: 31290
Study 20496613 — intervention group
Group type: EXPERIMENTAL
Intervention: Better-performing community facilitators
Number of subjects: 31290
Study 20496613 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly performing community facilitators
Number of subjects: 31290
Study 16752024 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg bid after a 400 mg loading dose
Number of subjects: 370
Study 16752024 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac SR 75 mg bid
Number of subjects: 370
Study 16752024 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 370
Study 16752024 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac SR
Number of subjects: 370
Study 15294086 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based nursing intervention
Number of subjects: 37
Study 15294086 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 37
Study 11473884 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 36
Study 11473884 — intervention group
Group type: COMPARATOR
Intervention: Control (Sterile water)
Number of subjects: 36
Study 9758713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteamine 0.5% with 0.01% benzalkonium chloride
Number of subjects: 14
Study 9758713 — intervention group
Group type: COMPARATOR
Intervention: Cystamine 0.5% with 0.01% benzalkonium chloride
Number of subjects: 14
Study 1654410 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) at doses of 800-1,200 mg daily for a median of 52 weeks
Number of subjects: 0
Study 1654410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1654410 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV)
Number of subjects: 0
Study 6411944 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated letter reminders
Number of subjects: 590
Study 6411944 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephoned reminders
Number of subjects: 590
Study 6411944 — intervention group
Group type: COMPARATOR
Intervention: No reminder (control group)
Number of subjects: 590
Study 6411944 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephoned or manual letter reminders
Number of subjects: 590
Study 31894446 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid genetic counseling and testing
Number of subjects: 285
Study 31894446 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 285
Study 30700317 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated (HYPO) radiotherapy
Number of subjects: 140
Study 30700317 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated (CF) radiotherapy
Number of subjects: 140
Study 30700317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HYPO and CF arms
Number of subjects: 140
Study 29021235 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine + ibuprofen
Number of subjects: 456
Study 29021235 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 456
Study 29021235 — intervention group
Group type: COMPARATOR
Intervention: ibuprofen
Number of subjects: 456
Study 26766737 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week lifestyle intervention (supervised exercise training and dietary advice)
Number of subjects: 50
Study 26766737 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 23291349 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose azithromycin
Number of subjects: 109
Study 23291349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 23291349 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose azithromycin (in non-eosinophilic severe asthma)
Number of subjects: 109
Study 23291349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in non-eosinophilic severe asthma)
Number of subjects: 109
Study 22314630 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (20 minutes of standard postoperative care and music twice daily on postoperative days 2 through 4)
Number of subjects: 100
Study 22314630 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 minutes of standard care with a quiet resting period twice daily on postoperative days 2 through 4)
Number of subjects: 100
Study 22314630 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 100
Study 22314630 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 19647524 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 69
Study 19647524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Treatment
Number of subjects: 69
Study 19647524 — intervention group
Group type: COMPARATOR
Intervention: Light Therapy
Number of subjects: 69
Study 17114878 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 1008
Study 17114878 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 1008
Study 15701209 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily) in RENAAL study
Number of subjects: 1513
Study 15701209 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg daily) in LIFE study
Number of subjects: 1513
Study 15701209 — intervention group
Group type: COMPARATOR
Intervention: Placebo in RENAAL study
Number of subjects: 1513
Study 15701209 — intervention group
Group type: COMPARATOR
Intervention: Atenolol in LIFE study
Number of subjects: 1513
Study 11699827 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release tablets of diclofenac sodium with HPMC and NaCMC (1:2:1 ratio)
Number of subjects: 0
Study 11699827 — intervention group
Group type: COMPARATOR
Intervention: Voveran SR
Number of subjects: 0
Study 11699827 — intervention group
Group type: COMPARATOR
Intervention: Dicloran SR
Number of subjects: 0
Study 9872487 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol patches (50 microg daily) with intrauterine system releasing 20 microg of levonorgestrel daily
Number of subjects: 40
Study 9872487 — intervention group
Group type: COMPARATOR
Intervention: Oral dose of 2 mg of estradiol and 1 mg of norethisterone acetate daily
Number of subjects: 40
Study 7520396 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment alone
Number of subjects: 102
Study 7520396 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent ejaculation alone
Number of subjects: 102
Study 7520396 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment with frequent ejaculation
Number of subjects: 102
Study 7520396 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 102
Study 3123302 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet therapy (administered nocturnally, at home, by continuous nasogastric infusion)
Number of subjects: 8
Study 3123302 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy (control group)
Number of subjects: 8
Study 30070045 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-weighing
Number of subjects: 0
Study 30070045 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly weighing
Number of subjects: 0